Explore QPS Podcasts — Insights From Bioanalysis and Drug Development Experts
Don’t miss our new Spotify Podcast channel: From Molecules to Medicines with QPS
Dive into a series of engaging podcasts where QPS scientists and industry leaders break down complex topics in bioanalysis, toxicology, cell and gene therapies, and regulatory science with clarity and depth. From cutting-edge methods like LC-MS/MS to real-world applications in biomarkers and therapeutic development, each episode brings expert perspectives straight to your ears. Whether you’re a researcher, clinician, or science enthusiast, our curated lineup offers valuable conversations that broaden your understanding and spark new ideas.
Join QPS scientist Tim Snow to explore how mass spectrometry helps characterize therapeutic oligonucleotide metabolites, with insights into metabolite identification and guidance for drug development.
Join David Dills, Regulatory Affairs Lead at QPS, for a practical guide to managing EU clinical trials through CTIS. Learn how to prepare submissions, meet RFI deadlines, address transparency rules and effectively transition to the new Annual Safety Report module while keeping your program on track.
QPS’s Kevin Vernarec explores how effective project management and clinical trial monitoring help sponsors reduce risk, protect data quality, control timelines and budgets, and move studies forward with confidence.
QPS Regulatory Affairs Lead David Dills shares strategies to improve health-authority interactions, align global regulatory plans, and navigate requirements throughout drug development.
QPS Missouri’s Brendon Bourg explores how QPS Central Safety Labs deliver comprehensive, reliable safety testing and fully managed lab services to streamline clinical trials and support drug development.
Join Jose Marcos, Vice President of Clinical Operations at QPS, as he discusses why early phase clinical trials are such a critical decision point in drug development.
In Part One of this series, join David Dills, Regulatory Affairs Lead at QPS, as he talks about key strategies to make health-authority interactions more productive.
In the final installment of this biosimilars series, Stacey Gottschall covers immunogenicity similarity assessment for biosimilars, walking us through the typical formats and the historical context behind the transition to a single-method approach.
In the second installment of this series, Stacey Gottschall explores best practices in PK similarity studies and the unique considerations for biosimilar PK assays compared with those for regular molecules or non-comparative studies.
In the first episode of this three-part series on biosimilars, Stacey Gottschall reviews the major biologics approaching patent cliffs and the opportunities this presents for drug developers.